ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
PALATIN TECHS INC
8.53
0.0000
成交量:
- -
成交額:
- -
市值:
830.22萬
市盈率:
- -
高:
8.53
開:
8.53
低:
8.53
收:
8.53
52周最高:
19.51
52周最低:
1.75
股本:
97.33萬
流通股本:
- -
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
每股收益(LYR):
-2.0233
淨資產收益率:
-378.67%
總資產收益率:
-70.26%
市淨率:
0.72
市盈率(LYR):
-4.22
資料載入中...
總覽
公司
新聞資訊
公告
帕拉丁宣佈口服MC4R激動劑PL7737在肥胖動物模型中取得積極臨床前療效數據
华尔街洞察
·
2025/07/15
Palatin公布口服MC4R激動劑PL7737在肥胖動物模型中積極臨床前功效數據
华尔街洞察
·
2025/07/15
Palatin口服肥胖新藥PL7737臨床前數據亮眼,計劃2026年啓動I期試驗
华尔街洞察
·
2025/07/15
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PTNT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","market":"US","secType":"STK","nameCN":"PALATIN TECHS INC","latestPrice":8.53,"timestamp":1776795540000,"preClose":8.53,"halted":8,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":973300,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"04-21 14:19:00 EDT 延時","open":8.53,"high":8.53,"low":8.53,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1776801600000},"marketStatusCode":2,"adr":0,"exchange":"OTCQB","adjPreClose":8.53,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","floatShares":0,"roa":"-70.26%","roe":"-378.67%","lyrEps":-2.023264,"shares":973300,"dividePrice":0,"high":8.53,"amplitude":0,"preClose":8.53,"low":8.53,"week52Low":1.75,"pbRate":"0.72","psRate":"0.93","week52High":19.505,"institutionHeld":0.1111,"latestPrice":8.53,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":8.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTNT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"PTNT","oldSymbol":"PTNT","defaultRemindTime":1762957800000,"newSymbol":"PTN","exchange":"OTCQB","type":"symbolChange","dateTimestamp":1762923600000},{"market":"US","date":"2025-08-12","symbol":"PTNT","defaultRemindTime":1755005400000,"type":"split","dateTimestamp":1754971200000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTNT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTNT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115580369","title":"帕拉丁宣佈口服MC4R激動劑PL7737在肥胖動物模型中取得積極臨床前療效數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1115580369","media":"华尔街洞察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115580369?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583435,"startTime":"0","endTime":"0","summary":"帕拉丁科技公司公布了其口服MC4R激动剂PL7737在肥胖动物模型中的积极临床前疗效数据。研究显示,PL7737与替西帕肽联用产生附加减肥效果,口服给药后在短短四天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药研究申请(IND),为后续开发铺路。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159628542","title":"Palatin公布口服MC4R激動劑PL7737在肥胖動物模型中積極臨床前功效數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1159628542","media":"华尔街洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159628542?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583426,"startTime":"0","endTime":"0","summary":"Palatin Technologies, Inc.今日宣布,其口服MC4R激动剂PL7737在肥胖动物模型中的临床前研究显示积极功效。研究结果表明,PL7737与tirzepatide联用可产生显著的加性减肥效果。效果惊人!口服PL7737在短短4天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药临床试验申请(IND)。这一进展突显了该药物在肥胖治疗领域的潜力,为未来临床试验奠定基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105523922","title":"Palatin口服肥胖新藥PL7737臨床前數據亮眼,計劃2026年啓動I期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1105523922","media":"华尔街洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105523922?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 19:33","pubTimestamp":1752579200,"startTime":"0","endTime":"0","summary":"生物医药企业Palatin Technologies近日公布其口服MC4R激动剂PL7737在肥胖症动物模型中取得突破性临床前数据。更值得注意的是,当PL7737与替西帕肽联用时,两者产生协同减重效应,减重幅度超越单一用药效果。根据研发规划,Palatin将于2025年第四季度向美国食品药品监督管理局提交PL7737的新药临床试验申请,预计2026年上半年公布首个人体试验数据。值得关注的是,PL7737已获得美国FDA授予的孤儿药资格认定,适应症为瘦素受体缺乏症相关肥胖。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}